Elevated concentration of lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease, including coronary artery disease, stroke, peripheral artery disease, and so on. Emerging data suggest that Lp(a) contributes to the increased risk for cardiovascular events even in the setting of effective reduction of plasma low-density lipoprotein cholesterol. Nevertheless, puzzling issues exist covering potential genetic factors, Lp(a) assay, possible individuals for analysis, a cutoff point of increased risk, and clinical interventions. In the Chinese population, Lp(a) exhibited a distinctive prevalence and regulated various cardiovascular diseases in specific ways. Hence, it is valuable to clarify the role of Lp(a) in cardiovascular diseases and explore prevention and control measures for the increase in Lp(a) prevalence in the Chinese population. This Beijing Heart Society experts' scientific statement will present the detailed knowledge concerning Lp(a)-related studies combined with Chinese population observations to provide the key points of reference.
Keywords: AMI, acute myocardial infarction; ASCVD, atherosclerotic cardiovascular disease; Apo, apolipoprotein; CAD, coronary artery disease; CAVS, calcific aortic valve stenosis; CVD, cardiovascular disease; CVE, cardiovascular event; FH, familial hypercholesterolemia; GWAS, genome-wide association analysis; KIV, Kringle IV; LA, lipoprotein apheresis; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); MACE, major adverse cardiovascular events; OxPL, oxidized phospholipids; PCSK9, proprotein convertase subtilisin/kexin type 9; SNP, single nucleotide polymorphism; T2DM, type 2 diabetes mellitus; atherosclerotic cardiovascular disease; calcific aortic value stenosis; lipoprotein(a); scientific statement.
© 2022 The Authors.